Institut Català de la Salut
[Saegeman V] Department of Microbiology and Infection Control, Vitaz, Sint-Niklaas, Belgium. Department of Infection Control, University Hospitals, Leuven, Belgium. [Cohen MC] Histopathology Department, Sheffield Children’s NHS FT, Sheffield, UK. [Abasolo L] Rheumatology Department, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IDISSC), Hospital Clínico San Carlos, Madrid, Spain. [Rello J] Grup de Recerca Clínica/Innovació en la Pneumònia i Sèpsia (CRIPS), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica En Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. Clinical Research, CHRU Nimes, Nimes, France. [Fernandez-Gutierrez B] Rheumatology Department, Hospital Clinico San Carlos, Madrid, Spain. [Fernandez-Rodriguez A] Microbiology Laboratory, Biology Department, Instituto Nacional de Toxicología y Ciencias Forenses, Las Rozas de Madrid, Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-09-14T08:14:50Z
2022-09-14T08:14:50Z
2022-06
SARS-CoV-2; Post-mortem microbiology; Volutrauma
SARS-CoV-2; Microbiología post mortem; Volutrauma
SARS-CoV-2; Microbiologia post mortem; Volutrauma
Background and Objective: A thorough understanding of the pathogenic mechanisms elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still requires further research. Until recently, only a restricted number of autopsies have been performed, therefore limiting the accurate knowledge of the lung injury associated with SARS-CoV-2. A multidisciplinary European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group of Forensic and Post-mortem Microbiology-ESGFOR team conducted a non-systematic narrative literature review among coronavirus 2019 disease (COVID-19) pneumonia cases assessing the histopathological (HP) effects of positive airways pressure. HP lung features were recorded and compared between mechanically ventilated (>24 hours) and control (ventilation <24 hours) patients. A logistic regression analysis was performed to identify associations between mechanical ventilation (MV) and HP findings. Methods: A PubMed and MEDLINE search was conducted in order to identify studies published between March 1st 2020 and June 30th 2021. Key Content and Findings: Seventy patients (median age: 69 years) from 24 studies were analysed, among whom 38 (54.2%) underwent MV longer than 24 hours. Overall, main HP features were: diffuse alveolar damage (DAD) in 53 (75.7%), fibrosis (interstitial/intra-alveolar) in 43 (61.4%), vascular damage—including thrombosis/emboli- in 41 (58.5%), and endotheliitis in only 8 (11.4%) patients. Association of DAD, fibrosis and vascular damage was detected in 30 (42.8%) patients. Multivariate analysis, adjusted by age and gender, identified MV >24 hours as an independent variable associated with DAD (OR =5.40, 95% CI: 1.48–19.62), fibrosis (OR =3.88, 95% CI: 1.25–12.08), vascular damage (OR =5.49, 95% CI: 1.78–16.95) and association of DAD plus fibrosis plus vascular damage (OR =6.99, 95% CI: 2.04–23.97). Conclusions: We identified that patients mechanically ventilated >24 hours had a significantly higher rate of pulmonary injury on histopathology independently of age and gender. Our findings emphasize the importance of maintaining a protective ventilator strategy when subjects with COVID-19 pneumonia undergo intubation.
Article
Versió publicada
Anglès
COVID-19 (Malaltia) - Complicacions; Respiració artificial - Complicacions; Pneumònia vírica; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Airway Management::Respiration, Artificial; Other subheadings::Other subheadings::Other subheadings::/adverse effects; DISEASES::Respiratory Tract Diseases::Lung Diseases::Pneumonia; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::manejo de la via aérea::respiración artificial; Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos; ENFERMEDADES::enfermedades respiratorias::enfermedades pulmonares::neumonía
AME Publishing Company
Annals of Translational Medicine;10(11)
http://dx.doi.org/10.21037/atm-22-605
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - VHIR [1655]